共 221 条
The production of biopharmaceuticals in plant systems
被引:73
作者:
Karg, Saskia R.
[1
]
Kallio, Pauli T.
[1
]
机构:
[1] Swiss Fed Inst Technol, Inst Microbiol, CH-8093 Zurich, Switzerland
关键词:
Biopharmaceutical;
Heterologous expression;
Molecular farming;
N-glycosylation;
Plants;
CELL-SUSPENSION CULTURES;
ANTIBODY EFFECTOR FUNCTIONS;
TRANSGENIC TOBACCO PLANTS;
HUMAN MONOCLONAL-ANTIBODY;
SNAIL LYMNAEA-STAGNALIS;
SINGLE-DOMAIN ANTIBODY;
HIGH-LEVEL EXPRESSION;
HIGH-YIELD PRODUCTION;
ALPHA-MANNOSIDASE-II;
CHAIN FV-ANTIBODY;
D O I:
10.1016/j.biotechadv.2009.07.002
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Biopharmaceuticals present the fastest growing segment in the pharmaceutical industry, with an ever widening scope of applications Whole plants as well as contained plant cell culture systems are being explored for their potential as cheap. safe, and scalable production hosts. The first plant-derived biopharmaceuticals have now reached the clinic. Many biopharmaceuticals are glycoproteins, as the Golg. N-glycosylation machinery of plants differs from the mammalian machinery, the N-glycoforms introduced on plant-produced proteins need to be taken into consideration Potent systems have been developed to change the plant N-glycoforms to a desired or even superior form compared to the native mammalian N-glycoforms This review describes the current status of biopharmaceutical production in plants for industrial applications. The recent advances and tools which have been utilized to generate glycoengineered plants are also summarized and compared with the relevant mammalian systems whenever applicable. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:879 / 894
页数:16
相关论文